The effects of tezepelumab were also greater in patients with T2 high asthma with higher levels of blood eosinophils, TSLP, FeNO, IL-5, IL-13 and serum periostin, and treatment with tezepelumab decreased the levelse of blood eosinophils, FeNO, IgE, IL-5, IL-13, periostin, TARC, and TSLP over a 52-week treatment period (Corren et al., 2021b; Menzies-Gow et al., 2021). This evidence concerns the gene IL5 and asthma.